Can you provide the last earnings date for REVIVA PHARMACEUTICALS HOLDI?
REVIVA PHARMACEUTICALS HOLDI (RVPH) last reported earnings on 3/30/2026.
NASDAQ:RVPH • US76152G2093
Past quarterly earnings results for REVIVA PHARMACEUTICALS HOLDI (RVPH), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.19 | - | 60.33% | - | - | |||
| Q3 2025 | -1.20 | -1.98 | 39.44% | 76.00% | - | - | ||
| Q2 2025 | -2.40 | -2.24 | -6.95% | 53.85% | - | - | ||
| Q1 2025 | -2.60 | -3.72 | 30.16% | 48.00% | - | - | ||
| Q4 2024 | -3.00 | -4.39 | 31.60% | 57.14% | - | - | ||
| Q3 2024 | -5.00 | -5.02 | 0.37% | 43.18% | - | - | ||
| Q2 2024 | -5.20 | -5.92 | 12.10% | 52.73% | - | - | ||
| Q1 2024 | -5.00 | -7.68 | 34.93% | 16.67% | - | - | ||
| Q4 2023 | -7.00 | -7.19 | 2.66% | 7.89% | - | - | ||
| Q3 2023 | -8.80 | -7.47 | -17.86% | -144.44% | - | - | ||
| Q2 2023 | -11.00 | -5.63 | -95.37% | -89.66% | - | - | ||
| Q1 2023 | -6.00 | -6.63 | 9.50% | 25.00% | - | - | ||
| Q4 2022 | -7.60 | -4.49 | -69.34% | -72.73% | - | - | ||
| Q3 2022 | -3.60 | -5.85 | 38.44% | -50.00% | - | - | ||
| Q2 2022 | -5.80 | -7.14 | 18.77% | -141.67% | - | - | ||
| Q1 2022 | -8.00 | -5.71 | -40.06% | -7,900.00% | - | - | ||
| Q4 2021 | -4.40 | -5.10 | 13.73% | -259.48% | - | - | ||
| Q3 2021 | -2.40 | -4.79 | 49.94% | -3,821.57% | - | - | ||
| Q2 2021 | -2.40 | -4.90 | 50.98% | - | - | - | ||
| Q1 2021 | -0.10 | - | - | - | - | |||
| Q4 2020 | -1.22 | - | - | - | - | |||
| Q3 2020 | -0.06 | - | - | - | - | |||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
REVIVA PHARMACEUTICALS HOLDI (RVPH) last reported earnings on 3/30/2026.
REVIVA PHARMACEUTICALS HOLDI (RVPH) missed EPS estimates and missed revenue estimates in the most recent quarter.